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Abstract 
The increase in opioid prescribing in many European countries over the last decade has 
raised concerns about associated diversion, overdose and mortality. Fentanyl is one of these 
synthetic opioids that is typically prescribed as a transdermal patch for pain that requires 
continuous pain relief and has been the focus of investigations due to reports of overdose 
and death. 
We report a case series of 14 drug addiction treatment entrants who entered treatment in 
one service located in the region of Southern Denmark from August 2015 to December 2015 
for smoking fentanyl patches. Clients presented with difficulties breathing and pains in the 
lungs. The clients had a history of past opioid use, including heroin. Relapses resulted in 
treatment disengagement. 
Immunoassays for fentanyl were used in the service. In some cases, false negative results 
occurred. Clients’ urine samples were subsequently analysed in a collaborating laboratory. 
Seven clients tested positive for fentanyl. One client was positive for both fentanyl and 
heroin. Analyses were also positive for other opioids and metabolites in six clients, 
predominantly codeine and oxycodone. Results from confirmatory analysis contributed to 
clearer insights into clients’ drug histories, which facilitated personalised care plans 
consisting of opioid agonist therapy informed by confirmed drug use. 
In Denmark, prescription levels of fentanyl are high, which has been accompanied by 
observations of diversion and smoking in a smaller population. In addition to revision of 
inappropriate prescribing to reduce diversion, we recommend increased reliance upon 
confirmatory drug analysis in the addiction treatment sector in Denmark. 
 
Keywords: fentanyl, transdermal patches, tampering, smoking fentanyl patches, addiction 
treatment, confirmatory drug analysis. 
Short title: Characteristics of opioid-maintained clients smoking fentanyl patches. 
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1 Introduction 
In the wake of the dire public health situation faced in North America concerning opioid use, 
where the synthetic opioid, fentanyl, has played a major role in overdose deaths,1,2 there 
has been an recent increase in focus on availability and misuse of fentanyl in Europe.3 
Multiple sources of fentanyl contribute to the overall supply, including pharmaceutical 
fentanyl diverted to the illicit market, and illicitly manufactured fentanyl and fentanyl 
analogs, also known as fentanils.4 Over the last ten years, a number of fentanyl analogs, 
such as acrylfentanyl, furanylfentanyl, acetylfentanyl, ortho-fluorofentanyl and carfentanil, 
have been detected in the EU.5-11 These substances have been linked to over 100 deaths 
across the EU and a number of acute intoxications.8-11 
Pharmaceutical fentanyl is often prescribed in the form of transdermal patches that deliver 
a fixed hourly rate of fentanyl through the skin.12 Fentanyl patches serve to relieve pain in 
cases of severe and debilitating disease that requires continuous pain management. The 
World Health Organisation’s list of Essential Medicines (2017) includes several new drugs, 
including transdermal fentanyl for pain in cancer patients with the aim to increase access to 
medicines for end-of-life care.13 
Misuse of fentanyl patches in the form of unsupervised dose escalation and altered routes 
of administration have been associated with adverse events, including respiratory 
depression.14 The risk of respiratory depression from fentanyl overdose is high.15 Common 
practices of inappropriate usage to induce psychoactive effects include oral administration 
of patches, smoking patches and injecting fentanyl extracted from patches to circumvent 
the fixed rate of fentanyl release.16 Reports have disclosed misuse of fentanyl patches in 
regional reports of drug-related harm from across Europe.14,17-19 
This paper describes a case series of clients seeking drug addiction treatment for fentanyl 
patch smoking in Denmark. It serves to highlight the challenges to addiction treatment 
posed by this opioid use and illustrates the benefits of collaboration between addiction 
services and analytical laboratories to obtain better insights into clients’ drug use to initiate 
personalised care plans and adequate administration of opioid agonist therapy. First, we 
review clients’ case notes and urine drug testing reports. Second, we present a mini-review 
of fentanyl use and misuse which accounts for different aspects of the fentanyl problem in 
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Denmark. From here, we discuss the contributions of confirmatory drug analysis in opioid 
agonist therapy treatment settings. 
2 Methods 
2.1 Case review 
A retrospective review of case notes was conducted for every client entering one addiction 
service in the Region of Southern Denmark from August 2015 to December 2015 for 
fentanyl patch smoking. Informed consent was obtained at treatment initiation. 
In addition to demographic information, including date of birth and gender, case notes 
contained information about clients’ drug histories recorded during the initial clinical 
assessments and descriptions of fentanyl use patterns. The case notes varied substantially in 
detail, reflecting a range in difficulty regarding client engagement. 
2.1.1 Background on the treatment service 
The treatment service is located in Fredericia municipality (Region of Southern Denmark) 
with a population of around 50000 people. Clients entering treatment for opioids receive 
opioid agonist therapy with administration of either methadone, buprenorphine or 
buprenorphine/naloxone (Suboxone®).20 These are dispensed daily by a nurse practitioner. 
The service offers distribution of sterile needle and syringes to reduce the sharing of 
injecting paraphernalia during continued opioid use. Individual treatment, built around 
counselling and cognitive behavioural therapy, is provided by a nurse practitioner and a 
consulting physician. The service has a treatment capacity of approximately 100 plus 
additional capacity for young adults (aged 15 to 30 years).21 
2.2 Urine analysis 
Urine analyses were performed in the treatment service using presumptive tests. In a 
subsequent attempt to gain more detailed information about clients’ drug use, urine 
samples were submitted for confirmed laboratory analysis. 
2.2.1 Presumptive tests for fentanyl 
On-site immunoassay urine multi-dip tests for fentanyl were used, which did lead to false 
negative results in a number of cases. Immunoassay tests were used ad hoc throughout 
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each client’s treatment period, such as after suspicion of continued fentanyl smoking. All 
clients included in the review were tested, but the frequency of testing and results/false 
negative results were not recorded systematically in the case notes. 
2.2.2 Laboratory confirmed urine toxicology 
Urine samples were analysed at a collaborating laboratory in the Department of Clinical 
Biochemistry, North Denmark Regional Hospital. Briefly, automated immunoassay screening 
for amphetamines, opioids, benzoylecgonine, benzodiazepines and cannabis and 
determination of creatinine was performed on a Cobas 6000 analyser (Roche Diagnostics). 
Positive results from immunoassays were confirmed using either full scanning gas 
chromatography/mass spectrometry (GC-MS) with mass spectra library search for 
benzodiazepines (after solid-phase extraction) or high-performance liquid chromatography 
and tandem mass spectrometry (LC-MS/MS) after diluting the sample with deuterium-
labelled internal standards. Prior to determination of the major metabolite 11-nor-delta-9-
tetrahydrocannabinol-9-carboxylic acid (THC-COOH) as a biomarker for cannabis use, solid-
phase extraction was performed.22 All results were reported qualitatively (positive/negative) 
according to cut-off levels, except for THC-COOH that was reported quantitatively and 
normalised to urine creatinine. Fentanyl and norfentanyl concentrations were measured by 
LC-MS/MS using 5 ng/mL as cut-off. 
Upon completion of laboratory confirmatory testing, results obtained for each client were 
immediately delivered to the clinical staff to inform of drugs consumed and adherence to 
medicines dispensed as opioid agonist therapy. 
3 Results 
3.1 Case series of addiction treatment entrants 
From August 2015 to December 2015, 14 clients began treatment for fentanyl smoking 
(Table 1). The mean age of the clients was 27.9 years (SD = 4.7; range: 23 to 37 years). Of 
the clients, 13 were males and one was female. During the initial clinical assessments, a 
nurse practitioner encouraged disclosure of current and past drug use. However, often 
these assessments failed to identify fentanyl smoking as the preferred route of 
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administration. False negative results from presumptive tests for fentanyl further 
complicated attempts to obtain a complete drug history. 
Of the clients, eight (57.1%) reported daily smoking of fentanyl patches prior to entering 
treatment and complained of shortness of breath, pain in the lungs and difficulties 
breathing. Daily fentanyl smokers tended to be older, more experienced in the practices of 
fentanyl smoking and would often pass on this information to inexperienced and younger 
clients (Table 1). 
All clients received buprenorphine and/or methadone as opioid agonist therapy. It was 
notable in the case notes that standard doses of buprenorphine/naxolone (Suboxone®) 
were often inadequate to prevent withdrawal. Several clients were treated with methadone 
instead, such as detected in urine of clients #4, 5, 6, 8 and 9 or received higher doses of 
buprenorphine (Table 1). Buprenorphine was detected in urine from clients #2 and 9. 
Four clients were new service entrants, whilst ten (71.4%) had previously received 
treatment for heroin and misused oxycodone. All 14 clients reported past use of heroin and 
misused oxycodone. Clients’ treatment journeys were characterised by disengagement from 
the service and continued drug use leading to negative impacts on treatment outcomes.  
3.1.1 Fentanyl smoking 
According to the clients, smoking fentanyl patches involved placing the whole patch or a 
smaller piece on aluminium foil. The foil was heated, and the smoke inhaled through a tube. 
Smoked patches were chewed or applied to the skin. The effects of fentanyl smoking were 
described as ‘strong’ and similar to injecting heroin. Frequent smoking of fentanyl patches 
or subsequent use of heroin and oxycodone were necessary to avoid withdrawal. 
3.1.2 Sources of obtaining fentanyl 
According to the Danish Misuse of Drugs Act, possession of scheduled drugs is a criminal 
offence and could lead to a fine and two years in prison.23 Fentanyl is classified under the 
Act as a Schedule B substance, which must only be used for medical and scientific purposes. 
Consequently, clients were generally cautious in disclosing their sourcing of fentanyl patches 
due to the illicit activities involved in supply and possession without a prescription. 
However, the 14 clients all admitted to obtaining fentanyl patches from the illicit market, 
though the exact route of diversion from legal sources to the illicit marketplace was often 
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unclear. Four clients (28.6%) reported the involvement of a local pain clinic, either issuing a 
prescription to the clients themselves (for back pain) or to other patients at the clinic who 
would sell them on the illicit market. As a result of this disclosure, a warning was issued 
from service staff to local GP surgeries and pain clinics in order to raise awareness of the 
potential misuse of fentanyl patches. 
Clients preferred patches manufactured by Orion Pharma, which have a higher 
concentration of fentanyl per surface area. Patches manufactured by Actavis were least 
sought after based on reports from the clients who identified the emission of unpleasant 
fumes when heated which caused discomfort and headaches. Table 2 presents a list of 
fentanyl patches licensed for use in Denmark. 
Fentanyl patches were relatively expensive and yet highly sought after. Patches with a 
release rate of 25 µg/h were sold for around 250 to 300 Danish Kroner (€30 to €40), patches 
with a release rate of 50 µg/h for 500 to 600 Danish Kroner (€70 to €80) and patches with a 
release rate of 100 µg/h for 1000 to 1200 Danish Kroner (€130 to €160). 
3.2 Interpretation of the analytical results 
Presumptive tests conducted by the clinical staff indicated that false negative test results 
could occur. Although these tests generally identified fentanyl in users with daily fentanyl 
smoking (57.1% of clients), false negative findings were encountered amongst clients 
reporting fentanyl smoking less frequently. 
Confirmatory drug analysis provided measures of fentanyl and norfentanyl concentrations 
as well as confirmation of other drug use. Of the 14 clients, nine were tested. Clients #5,6 
and 8 were tested on multiple occasions (Table 1). Of the nine clients tested, seven were 
positive for both fentanyl and norfentanyl (77.8%). For one client (#2) only norfentanyl was 
detected above the threshold. 
3.2.1 Urine fentanyl / norfentanyl concentrations 
The mean concentrations of fentanyl and norfentanyl were 466 ng/mL (range: 8.2 to 5000 
ng/mL) and 1472 ng/mL (range: 10.4 to 11030 ng/mL), respectively (Table 1). After 
normalisation by urinary creatinine concentration, this corresponded to a mean value of 23 
mg fentanyl/mol creatinine (range: 0.70 to 230 mg/mol) and 82 mg norfentanyl/mol 
creatinine (range: 0.83 to 507 mg/mol). 
  8 
3.2.2 Detection of other drugs in urine 
The most common illicit drugs were cannabis (88.9% of tested clients), cocaine (44.4%) and 
amphetamine (33.3%) (Table 1). In total, four of the tested clients (44.4%) were positive for 
a biomarker metabolite for smoking crack cocaine (ecgonidine) (> 50 ng/mL). The heroin 
metabolite 6-monoacetylmorphine was detected in the urine of two clients (> 10 ng/mL), of 
which one (client #4) was also positive for fentanyl (Table 1). Analyses were also positive for 
other opioids and metabolites in six clients (66.7%), including codeine, morphine, 
oxycodone and oxymorphone. Client #7 tested positive for both fentanyl and oxycodone 
(Table 1). 
3.2.3 Inhalation as exposure route 
Results from the confirmatory analysis suggested that urine concentrations of 
fentanyl/norfentanyl achieved from inhalation of thermally generated aerosols of fentanyl 
can exceed those measured after patch application following medical guidelines for 
usage.24,25 Previous findings support that exposure to volatised fentanyl can cause 
respiratory depression in a dose-dependent manner in mice26 and rapidly elevate the blood 
fentanyl concentration, which increases the risk of overdose.27,28 However, pyrolytic 
products from the materials used in patches may potentially reduce the absorption of 
fentanyl inhaled from patch smoking. Patch type and size may also influence the amount of 
fentanyl absorbed through this route of administration. 
3.3 Comments on adverse health effects 
Fentanyl patches contain various types of polymers, such as polyethylene terephthalate 
(PET), which is used in backing film, membranes and adhesives. Analyses of pyrolytic 
products of PET have identified a range of volatile compounds, including carbon dioxide, 
aldehydes, aliphatic hydrocarbons, aromatic hydrocarbons, esters, methyl alcohol and 2-
methyl-1,3-dioxolane.29,30 Pyrolytic products from fentanyl and materials used in the 
patches are potentially toxic when inhaled.31 However, whether clients’ complaints of chest 
pain and difficulties breathing, as reported by 57.1% of clients, were a result of smoking 
fentanyl patches or other factors like tobacco smoking, smoking crack cocaine, and sleeping 
rough is not clear. Of note is that 1 case report has described a patient diagnosed with 
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pulmonary alveolar proteinosis (PAP) who reported smoking fentanyl patches and 
presented with similar symptoms, including shortness of breath, coughing and chest pain.32 
3.4 Impact on addiction treatment from laboratory analysis 
The results from the laboratory analysis supported the development of personalised and 
effective treatment plans as well as a better understanding of drug use in the region. Under-
reporting of drugs by clients, combined with the uncertainties arising from false negative 
results conflicting with self-reported fentanyl consumption, resulted in confusion and poor 
understanding of clients’ histories. Results from confirmatory analysis were used to re-
assess clients’ drug histories during clinical assessment to determine which types of 
substance use to focus on during individual counselling. Insights into fentanyl smoking, 
initiated by further client evaluation informed by the concentrations of fentanyl measured, 
eventually helped explain smoking practices and the reported adverse symptoms, including 
difficulties breathing, which had not previously been encountered in the service. 
Use of heroin and oxycodone to prevent withdrawal from fentanyl smoking had not 
previously been reported amongst service clients. Positive results for multiple opioid usage 
led clinical staff to make adjustments in opioid agonist therapy to reduce experiences of 
withdrawal amongst these clients and discourage ongoing fentanyl smoking and heroin use. 
This was achieved by increasing dispensed doses or using other medication, such as 
switching clients from buprenorphine to methadone. 
Confirmatory urinary analyses, in conjunction with, and in addition to, clinician-initiated 
assessments, may be helpful in addiction treatment settings across the Danish regions to 
gain more detailed insights into clients’ drug histories. 
4 Discussion 
In our case series of fentanyl smoking, clients presented with opioid dependence, 
withdrawal, chest pains and difficulties breathing as potential harms relating to fentanyl 
smoking. Polysubstance use, including opioids, benzodiazepines and cannabis, were also 
recorded in most clients. The addition of confirmatory drug analysis to clients’ case notes 
contributed to more personalised treatment plans and medication monitoring from 
increased specificity of drug usage, making it a useful assessment tool in addiction 
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treatment centred around personalised counselling and opioid agonist therapy. Next, we 
review fentanyl use, misuse and associated harm in Denmark to provide a background to 
the case series which will lead to a discussion of the need for further implementation of 
confirmatory drug analysis in addiction treatment in Denmark. 
4.1 Fentanyl in Denmark: a mini-review 
4.1.1 Fentanyl use in Denmark 
The first fentanyl patch entered the Danish market in 1996. The continuous release of 
fentanyl provided by the transdermal delivery system was preferred over oral sustained 
formulations in cancer patients.33 In less than a year, fentanyl had become one of the most 
commonly used opioids for treatment of cancer patients in Denmark.34 Fentanyl patches 
were eventually approved for non-malignant types of pain and 1996 to 2003 saw substantial 
growth in use from 0.14 to 2.27 defined daily doses (DDD) per 1000 inhabitants per day, a 
16-fold increase.34 From 2003 to 2004, the number of patients prescribed opioids increased 
by approximately 5000, mainly due to increased use of oxycodone, buprenorphine and 
fentanyl.35 By 2008, fentanyl patches and oxycodone accounted for more than half of the 
annual opioid prescription costs.36 From 2010 through 2014, fentanyl use in Denmark 
remained stable, but higher compared to in the other Nordic countries measured in DDD 
per 1000 inhabitants per day.37 
4.1.2 Fentanyl misuse and harm 
Simonsen et al. performed a review of post-mortem casework in Denmark and found in 
2012 that 0.5% of cases of drug-related deaths (ten individuals) involved fentanyl.38 The 
2016 Annual Drug Report for Denmark highlights a national decrease in the number of 
heroin users in drug treatment between 2010 to 2014, whereas the number of other opioid 
users has increased.39 However, the number of treatment entrants for fentanyl in Denmark 
is not recorded in these data. 
The Danish Medicines Agency (DMA) collects information about suspected side effects to 
medicines known as adverse drug reactions (ADRs). ADRs are likely to go undetected and 
under-reported for a number of reasons, such as failure to draw links between adverse 
events and drugs consumed.40 Since 1996, the DMA has received 109 ADRs reports related 
to fentanyl.41 The number of reports was relatively stable from 1996 through 2007. 
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However, a 10-year analysis shows a 250% increase in the mean number of reports from 2.4 
between 1997 to 2006 to 8.4 between 2007 and 2016.41 There were three reports in 2009, 
of which one was serious, and 12 reports in 2014 (five serious and one fatal) as compared 
with 18150 fentanyl prescriptions in 2009 and 19504 in 2014. The proportion of serious 
reports between 2007 to 2016 is 105% higher than between 1997 to 2006 and includes two 
reports with fatal outcome (one in 2013 and one in 2014).41  
Oral consumption of fentanyl contained in patches has been reported in a case report from 
2014. A patient (34 year-old male) steeped two fentanyl patches in a cup of tea and drank 
it.14 He was found unconscious at home with convulsions and respiratory depression. On 
arrival at the hospital, intravenous naloxone administered over a 4-hour period resulted in 
reversal of the fentanyl effects. 
In the preceding section, we present recommendations for prescribing and diversion 
prevention practices and addiction treatment for fentanyl in Denmark. 
4.2 Misuse of fentanyl in the context of medicine regulation 
The increasing number of ADRs in the past ten years is likely related to increased fentanyl 
use since the mid-1990s,34 especially amongst an ageing population. However, the recent 
increase in the proportion of serious ADRs reports, as well as reports of diversion, smoking 
and mortality warrants a review of potent opioid use in Denmark. 
Prescribers’ decisions to prescribe fentanyl should reflect evidence on benefits and harms as 
well as the wider public health concerns about fentanyl, including risks of diversion.42 
Medicine regulators in Denmark should stress the risks linked to fentanyl patches by 
including and emphasising information provided in summaries of product characteristics 
(SPCs) about potential diversion and smoking. Fentanyl is used for management of very 
severe pain and as part of end-of-life care.13 When fentanyl is only prescribed to patients 
where fentanyl is the optimal choice, the risk of diversion is most likely reduced. Though 
there are difficulties in identifying and working with patients who obtain fentanyl patches 
with the aim of diversion or misuse,43 safe opioid prescribing, taught through campaigns and 
guided by policy guidelines,44 can help prescribers reduce rates of inappropriate prescribing. 
Improved prescribing practice includes comprehensive initial assessments, regular 
monitoring and review of patients, including thorough routine drug testing, and nondrug 
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therapy,45 such as physical therapy, especially amongst long-term opioid users in chronic 
pain where the risks of opioids may outweigh the benefits.46 The overall aim should be to 
reduce inappropriate prescribing and subsequently reduce diversion of fentanyl patches 
through illicit channels which was the main source of obtaining patches amongst clients in 
this case series. 
Education of patients on proper storage and disposal of medicines and take-back schemes 
of unwanted medicine, such as ‘patch-for-patch’ return programmes,47 could help ensure 
that left-over fentanyl is always returned to pharmacies for safe disposal. A study measured 
the amount of fentanyl in patches worn for 72 h and found 24 to 84.4% of the content 
remained unreleased from the patches.48 Poor adhesion can result in premature 
replacement after less than 72 h, which can result in substantial amounts of unreleased 
fentanyl in these patches.49,50 In hospitals, used patches must therefore be returned to 
hospital pharmacies and safely disposed. Though these systems help to stop the diversion of 
pharmaceutical waste and medicines to the illicit market and unintended individuals,51 poor 
adherence to policy guidelines and lack of understanding of the effectiveness is an 
important area for improvement of fentanyl regulation.52,53 
The pharmaceutical formulation of fentanyl patches is also an aspect of consideration, as 
current transdermal delivery systems do not offer protection against tampering. As reported 
by the clients in this case series, patches can be easily prepared for smoking with inhalation 
of vapors resulting in rapid onset of psychoactive effects as desired by the clients. 
Tampering-resistant formulations have been developed and are being tested, including a 
fentanyl patch with integrated ceramics (geopolymer granules) to protect against common 
tampering techniques.12 However, further research is needed to determine whether such 
tampering-resistant patches will curb the harm caused by fentanyl.54 
4.3 Misuse of fentanyl amongst addiction treatment clients 
Fentanyl smoking, which has not previously been reported in Denmark, appears to be 
confined to smaller, isolated populations of opioid users who are vulnerable to dependence, 
withdrawal and relapse. Findings indicate that fentanyl patches are sought after for 
purposes of tampering to use fentanyl excessively, resulting in demand for drug treatment 
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provision. This is consistent with reports from other European countries, Canada and the 
United States.18,55,56 
Urine concentrations of fentanyl measured amongst some clients exceeded those measured 
after appropriate patch application.24,25 Furthermore, fentanyl smoking was associated with 
use of heroin and oxycodone. Use of multiple opioids may explain the severe level of 
dependence and withdrawal affecting many of the clients. Previous research have shown 
that opioid agonist therapy may be perceived as inadequate amongst opioid-dependent 
individuals with high withdrawal scores,57 with resulting continuing episodes of drug use. In 
this present study, only one client (less than 10%) was abstinent from fentanyl after 12 
months treatment. Inadequate doses may explain the difficulties encountered during the 
treatment of the 14 clients where many disengaged from the service due to relapse, 
highlighting the impact from laboratory testing to get an full overview of clients’ opioid use 
to adjust opioid agonist therapy accordingly. 
5 Perspective 
5.1 The importance of confirmatory drug analysis 
In this case series, using confirmatory tests in addiction services has been shown to improve 
clinicians’ understanding of clients’ use of opioids and help in designing personalised 
treatment plans based on opioid agonist therapy. Confirmatory testing added significant 
value to presumptive testing, as these produced false negatives and did not provide a 
complete overview of drug usage. Next, we discuss the contributions from further 
collaboration between drug addiction services and analytical laboratories on a national 
scale. 
5.1.1 Pitfalls of on-site screening 
Using self-report and clinician-administered questionnaires are common practice to assess 
history of drug use in addiction treatment, although these are vulnerable to omission by 
clients and may suffer in accuracy and detail.58 As part of the routine clinical care in the 
service, drug use was also monitored with the use of on-site screening with immunoassays. 
However, the general limitations of immunoassays in urine drug testing and pain 
management include their lack of sensitivity and selectivity.59-61 Although not detected in 
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clients investigated here, immunoassays for fentanyl have been reported to cross-react with 
the drug risperidone causing false positives,62 and fentanyl has been reported to cause false 
positives in immunoassays for lysergic acid diethylamide (LSD).63 A preliminary study done 
by Health Canada found that presumptive tests gave false positives and false negatives in 
samples with known content of illicit fentanyl and fentanyl analogs.64 With the presence of 
tampering of prescription opioids (e.g. patch smoking) and polysubstance use in Denmark, 
immunoassays appear to no longer be sufficient as a tool to accurately determine drug use 
amongst clients entering drug addiction treatment and would benefit from support from 
confirmatory analysis.65 
5.1.2 Poor adherence to drug testing guidelines 
According to the Danish guidelines for opioid agonist therapy, urine drug testing is not 
mandatory.66 However, if immunoassays are used, positive results must be confirmed by 
mass spectrometry. The Danish Society of Clinical Biochemistry has published guidelines for 
urine drug testing, which recommend the use of confirmatory analysis.67 Yet, to the best of 
our knowledge, these guidelines are poorly implemented in clinical practice. Better use of 
drug testing amongst primary care patients undergoing pain management with opioid could 
reduce the risk of dependence and provide better understanding of opioid misuse and non-
compliance (e.g. amongst patients selling their medicine on the illicit market). The 
limitations of on-site urine screening reported at the treatment service, including the lack of 
proper registration of test use, is evidence of a gap in testing procedures in the drug 
addiction treatment sector in Denmark, which should be improved by implementation of 
confirmatory analysis. 
5.1.3 Biomarkers for fentanyl smoking 
Analytical procedures to discriminate between fentanyl smoking and other routes of 
administration are currently unavailable. A pyrolysis GC-MS study of potential biomarkers of 
smoked fentanyl found propioanilide and semi-volatiles (pyridine, styrene, benzaldehyde, 
aniline, phenylacetaldehyde, 2-chloroethylbenzene) as the major components after aerobic 
pyrolysis of fentanyl.68 Upon inhalation, these products will undergo hepatic metabolism 
and the resulting metabolites may be difficult to distinguish from food components, traces 
of environmental pollutants, products from tobacco smoking and endogenous compounds. 
Increased reliance upon specialised laboratories in addiction treatment settings may 
  15 
facilitate development of methods to detect new substances reported and biomarkers 
relevant to specific types of reported tampering, such as fentanyl smoking.69 A retrospective 
toxicological investigation of hair samples collected from 24 victims of drug facilitated crime 
demonstrate the value of segmental hair analysis to determine fentanyl concentrations and 
confirm exposure,70 and may represent another important area of drug analysis 
development. 
5.2 A national shift in drug testing 
Advances in the use of high resolution mass spectrometry or triple quadrupole mass 
spectrometry in clinical and forensic toxicology have facilitated the development of routine 
methods where hundreds of compounds can be detected simultaneously.71-73 Greater 
access to these methods is important to assure a high quality in urine drug testing in 
addiction treatment,65 especially when confronted by new forms of drug use, such as 
fentanyl smoking. For this purpose, mass spectrometry is superior to immunoassays and we 
propose a shift in drug testing practice in Denmark where clinical laboratories play a greater 
role. 
6 Conclusion 
During a 5-month period in 2015, 14 clients sought treatment for fentanyl smoking in an 
addiction treatment service in Fredericia, Region of Southern Denmark, as compared to 
none the year before. This took up approximately 13% of treatment capacity in the 
service.21 The rise of fentanyl smoking in addition to, or replacement of, heroin and 
oxycodone diverged from regional patterns in substance use, but is consistent with trends 
recorded across Europe. According to EU-level data, the ‘opioid problem’ increasingly 
involves both traditional opioids (heroin), prescription opioids and illicitly manufactured 
fentanyl analogs.74 
In Denmark, the national level of fentanyl prescribing is high37 with confirmed, but unknown 
levels of diversion of fentanyl to the illicit market, reported deaths linked to fentanyl as well 
as inappropriate route of administrations in populations of opioid users gaining access to 
addiction treatment. These observations of diversion, misuse and deaths have prompted a 
need to revise prescribing practices of opioids to minimise diversion of fentanyl patches to 
the illicit market. 
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We encourage collaboration between clinical staff in the drug addiction treatment field and 
analytical laboratories to analyse drug samples, urine and blood, as part of a client’s 
treatment journey. In the case series presented here, confirmatory analyses provided 
important insights into clients’ drug use and results added to self-reported usage data to 
instigate personalised care plans based on confirmed drug use and adjustments of opioid 
agonist therapy (dose and medication). Overall, more personalised and specific care plans 
have the potential to improve addiction treatment in Denmark and reducing drug-related 
harm. 
6.1 Limitations 
In the analysis of data from this case series, we make no claims of statistical generalisation. 
The lack of data for investigating the extent of fentanyl misuse and harm across all regions 
of Denmark makes it difficult to determine the full extent of the problem. None of the 
clients reported exposure to fentanyl analogs and the analysis of these substances was not 
included in the testing procedure. Several fentanyl analogs, including acrylfentanyl, have 
since been identified in Denmark,6 and available evidence now suggests an association 
between heroin use and exposure to fentanyl analogs in reports from EU countries.75 It is 
recommended that laboratory analysis investigate for fentanyl analogs amongst opioid 
users currently undergoing drug treatment.65 We also recognise that the applied urine 
testing methods do not distinguish between different routes of fentanyl administration 
(appropriate application to the skin versus smoking). Furthermore, the retrospective design 
of the study precludes additional data collection. Areas of interest to an investigation of 
fentanyl smoking, such as sourcing of fentanyl, treatment outcomes, including number of 
relapses, and further confirmatory testing (to include specific biomarkers and other opioids) 
were under-reported or unavailable from the case notes and the toxicological investigation. 
6.2 Implications for research 
While case reports/case series can represent the first and only source of information of rare 
or new events, they do not offer the same insights as other research designs used in the 
field of addiction research. We propose a future investigation of fentanyl smoking and 
injection of fentanyl extracted from diverted patches in large national research, which 
includes confirmatory drug testing programmes that explores potential biomarkers of 
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smoked fentanyl patches, such as propioanilide and semi-volatiles including pyridine, 
styrene, benzaldehyde, aniline, phenylacetaldehyde and 2-chloroethylbenzene.68 
Implementing routine laboratory testing within addiction treatment services would come 
with costs to carry out these tests, which is currently difficult to justify in the absence of an 
evidence-base for their added value in health care provision, especially in the presence of 
recent cuts in funding in the sector. Reduced treatment demand and length as well as fewer 
relapses due to improved personalised care would be associated with a cost reduction for 
services. Systematic comparisons of treatment outcomes, for instance in services using 
frequent laboratory confirmed testing compared to services relying predominantly on self-
reported drug use and presumptive tests, could provide data to estimate the impact of 
laboratory analysis. Importantly, a case series design does not allow to make such 
assessments. 
With improved detection of drug use in addiction services, data could feed into to national 
and internationally early warning systems. Real-time data or data produced with minimal 
delay from services across Denmark could be used to informed other services and users of 
potential risks from new drugs and drug trends, such as fentanyl smoking. Improvement of 
early warning systems presents another area for further research. 
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Table 1: Demographics and confirmed analytical findings for clients in addiction treatment for fentanyl patch smoking tested between August 
2015 and July 2016 
Clienta Gender Age 
Creatinineb 
mmol/L 
Fentanylc 
ng/mL 
Norfentanylc 
ng/mL 
Fentanyl/Creatinined 
mg/mol 
Norfentanyl/Creatinined 
mg/mol 
Other drugs detectede,f 
1 Male 37 No test results available Codeine, morphine, 
6-monoacetylmorphine, 
desmethyldiazepam. 
2 Male 36 12.2 < 5 18.4 Concentration below 
cut-off 
1.5 Buprenorphine glucuronide, 
methylphenidate, 
oxymorphone, THC-COOH. 
3 Male 34 12.4 8.7 10.4 0.7 0.8 Amphetamine, benzoylecgonine, 
THC-COOH, 
methylphenidate. 
4 Male 34 24.1 18.8 762 0.8 32 Codeine, morphine,  
6-monoacetylmorphine, 
benzoylecgonine, ecgonidine,  
THC-COOH, 
EDDP, desmethyldiazepam. 
5 Male 32 11.8 15.3 182 1.3 15 THC-COOH, EDDP. 
 6.7 120 316 18 47 
17.5 36.9 704 2.1 40 
6 Male 28 32 34.5 211 1.1 6.6 THC-COOH, EDDP, 
methylphenidate. 
 25.5 28.9 221 1.1 8.7 
13.1 123 843 9.4 64 
10 8.2 40 0.8 4 
7 Male 28 20.1 615 3808 31 189 Amphetamine,  
benzoylecgonine, ecgonidine, 
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THC-COOH,  
oxycodon, oxymorphone. 
8 Female 24 14.6 < 5 < 5 Concentration below cut-off Amphetamine, benzoylecgonine, 
ecgonidine,  
THC-COOH, diazepam, morphine, 
EDDP, 
methylphenidate. 
 21.8 5000 11030 230 507 
10.5 37.6 2122 3.6 202 
9 Male 24 15 15.6 343 1 23 Benzoylecgonine, ecgonidine, 
buprenorphine glucuronide,  
THC-COOH, 
morphine, EDDP, 
desmethyldiazepam. 
 
a Some clients were tested on multiple occasions. 
b Urine concentration of creatinine (shown only for positive fentanyl or norfentanyl results). 
c Threshold concentration (cut-off) used for fentanyl and norfentanyl was 5 ng/mL. 
d Normalised ratio to urinary creatinine concentration calculated by dividing fentanyl or norfentanyl concentrations with creatinine 
concentrations with rejection of samples with creatinine below 0.5 mmol/L. 
e Confirmed by gas- or liquid chromatography with mass spectrometry (GC-MS, LC-MS/MS). 
f EDDP: 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine; THC-COOH: 11-nor-9-carboxy-delta-9-tetrahydrocannabinol. 
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Table 2: Fentanyl patches licensed for use in Denmark. 
Name of product Company name Dose (µg/h) 
Durogesic® 
 
Janssen-Cilag 12, 25, 50, 75, 100 
Fentanyl Orion® Orion Pharma 12, 25, 50, 75, 100 
Fentanyl Sandoz® Sandoz 12, 25, 50, 75, 100 
Matrifen® Takeda Pharma 12, 25, 50, 75, 100 
Fentanyl Mylan® Mylan AB 12, 25, 50, 75, 100 
 
 
 
